These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 27019793)

  • 1. New developments and controversies in iron metabolism and iron chelation therapy.
    Kontoghiorghe CN; Kontoghiorghes GJ
    World J Methodol; 2016 Mar; 6(1):1-19. PubMed ID: 27019793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Geneen LJ; Dorée C; Estcourt LJ
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012349. PubMed ID: 36877640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
    Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.
    Kontoghiorghes GJ
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
    Kolnagou A; Kontoghiorghes GJ
    Front Biosci (Landmark Ed); 2018 Jan; 23(6):1082-1098. PubMed ID: 28930590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
    Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
    Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
    Kontoghiorghes GJ; Neocleous K; Kolnagou A
    Drug Saf; 2003; 26(8):553-84. PubMed ID: 12825969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial.
    Premawardhena A; Perera C; Wijethilaka MN; Wanasinghe SK; Rajakaruna RHMG; Samarasinghe RANKK; Williams S; Mettananda S
    BMJ Open; 2024 Feb; 14(2):e077342. PubMed ID: 38331857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A risk-benefit assessment of iron-chelation therapy.
    Porter JB
    Drug Saf; 1997 Dec; 17(6):407-21. PubMed ID: 9429839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases.
    Kontoghiorghes GJ
    Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.
    Kontoghiorghes GJ; Kolnagou A; Peng CT; Shah SV; Aessopos A
    Expert Opin Drug Saf; 2010 Mar; 9(2):201-6. PubMed ID: 20059374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of iron salts, haemosiderins, and chelating agents on the lymphocytes of a thalassaemia patient without chelation therapy as measured in the comet assay.
    Anderson D; Yardley-Jones A; Vives-Bauza C; Chua-Anusorn W; Cole C; Webb J
    Teratog Carcinog Mutagen; 2000; 20(5):251-64. PubMed ID: 10992272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
    Kontoghiorghes GJ; Pattichis K; Neocleous K; Kolnagou A
    Curr Med Chem; 2004 Aug; 11(16):2161-83. PubMed ID: 15279556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.